This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.


Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


CRISPR-Cas9

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (10:25, 17 January 2022) (edit) (undo)
 
(83 intermediate revisions not shown.)
Line 1: Line 1:
-
<StructureSection load='4qyz' size='450' side='right' scene='74/742625/Cv/4' caption=''>
+
<StructureSection load='' size='350' side='right' scene='74/742625/Cv3/13' caption='Cas9 complex with RNA (PDB code [[4zt0]])'>
-
==Background==
+
'''Part I'''
 +
 
 +
SEE ALSO
 +
*[[CRISPR-Cas9 Part II]]
 +
*[[CRISPR-Cas]]
 +
'''Background'''
 +
 
Highlights
Highlights
-
*CRISPR-Cas9 is a powerful tool to modulate transcription in wide range of cell types.
+
*'''CRISPR-Cas9 (CRISPR type II-A)''' is a powerful tool to modulate transcription in wide range of cell types.
*An expanding set of CRISPR-based transcription effectors is available.
*An expanding set of CRISPR-based transcription effectors is available.
*Gene networks can be efficiently probed and modified for biotechnology applications.<ref name="Did">PMID:27344519</ref>
*Gene networks can be efficiently probed and modified for biotechnology applications.<ref name="Did">PMID:27344519</ref>
Line 11: Line 17:
Since the early days of genetic engineering there has been a need for control of gene expression. Naturally occurring transcription factors (TFs) have traditionally been used to achieve this goal (reviewed in <ref name="Prin1">PMID:24781324</ref>). However, their limited DNA binding sequence space required installing specific sequences within the transcription regulatory elements of the target genes. This can be technically difficult and may have unintended consequences on gene expression. Zinc fingers (ZFs) and transcription activator-like effectors (TALEs) were developed to overcome the fixed binding sequence requirements of native TFs. However, both ZFs and TALEs have significant limitations. ZFs have complicated design criteria and large highly repetitive TALE genes are difficult to synthesize and clone (reviewed in <ref name="Prin2">PMID:23718948</ref><ref name="Prin3">PMID:24584096</ref>). These challenges have recently been overcome using CRISPR-Cas9 based TFs. The biochemical properties of CRISPR-Cas9 based TFs that enable such flexibility and describe their applications to synthetic gene circuit design and multi-plexed perturbation of native gene networks.<ref name="Did">PMID:27344519</ref>
Since the early days of genetic engineering there has been a need for control of gene expression. Naturally occurring transcription factors (TFs) have traditionally been used to achieve this goal (reviewed in <ref name="Prin1">PMID:24781324</ref>). However, their limited DNA binding sequence space required installing specific sequences within the transcription regulatory elements of the target genes. This can be technically difficult and may have unintended consequences on gene expression. Zinc fingers (ZFs) and transcription activator-like effectors (TALEs) were developed to overcome the fixed binding sequence requirements of native TFs. However, both ZFs and TALEs have significant limitations. ZFs have complicated design criteria and large highly repetitive TALE genes are difficult to synthesize and clone (reviewed in <ref name="Prin2">PMID:23718948</ref><ref name="Prin3">PMID:24584096</ref>). These challenges have recently been overcome using CRISPR-Cas9 based TFs. The biochemical properties of CRISPR-Cas9 based TFs that enable such flexibility and describe their applications to synthetic gene circuit design and multi-plexed perturbation of native gene networks.<ref name="Did">PMID:27344519</ref>
-
Many bacteria and archaea possess an adaptive immune system consisting of repetitive genetic elements known as clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) proteins. Similar to RNAi pathways in eukaryotes, CRISPR–Cas systems require small RNAs for sequence-specific detection and degradation of complementary nucleic acids. Cas5 and Cas6 enzymes have evolved to specifically recognize and process CRISPR-derived transcripts into functional small RNAs used as guides by interference complexes. Our detailed understanding of these proteins has led to the development of several useful Cas6-based biotechnological methods. The structures, functions, mechanisms, and applications of the enzymes responsible for CRISPR RNA (crRNA) processing, highlighting a fascinating family of endonucleases with exquisite RNA recognition and cleavage activities are reviewed.<ref name="Rev3">PMID:25468820</ref>
+
====Transcriptional regulation with CRISPR-Cas9====
-
==CRISPR–Cas systems and crRNA biogenesis==
+
[[Image:1-s2.0-S0958166916301537-gr1.jpg|left|450px|thumb|'''Figure 1.''' Overview of Cas9 nuclease and dCas9-based transcription factors. (a) Wild-type Cas9 endonuclease guided by crRNA:tracrRNA to a specific site in DNA creates a double-stranded DNA break. (b) dCas9, nuclease deactivated mutant of Cas9, is an RNA programmable DNA binding protein. It can act as a steric repressor of transcription in prokaryotes and eukaryotes. sgRNA is an artificial chimeric molecule consisting of crRNA and tracrRNA molecules connected with a short loop. (c) dCas9 fusion with various transcription effectors can be used to repress or activate transcription. (d) Effector domains can be recruited by sgRNA in addition to dCas9 for enhanced activity. (e) sgRNA can be modified with specific protein binding hairpins to concurrently recruit repressor or activator domains in the same cell.<ref name="Did">PMID:27344519</ref>]]
 +
{{Clear}}
-
Most prokaryotes employ an RNA-based adaptive immune system known as CRISPR–Cas to identify and eliminate genetic parasites.<ref name="Rev3">PMID:25468820</ref> Upon detecting viral or plasmid DNA in the cell, bacteria and archaea with active CRISPR systems respond by integrating short fragments of foreign DNA into the host chromosome at one end of the CRISPR locus (Figure 1) <ref name="Rev36">PMID:17379808</ref><ref name="Rev37">doi:10.1038/nature09523</ref><ref name="Rev38">doi:10.1111/mmi.12640</ref>. Such loci serve as molecular vaccination cards by maintaining a genetic record of prior encounters with foreign transgressors. The defining feature of CRISPR loci is a series of direct repeats (~20–50 bp) separated by unique spacer sequences of a similar length (Figure 1) <ref name="Rev39">doi:10.1186/1745-6150-1-7</ref><ref name="Rev310">doi:10.1186/gb-2007-8-4-r61</ref>. Following transcription, CRISPR sequences are processed into short CRISPR-derived RNAs (crRNAs) <ref name="Rev312">doi:10.1126/science.1159689</ref>:
+
Cas9 is a key protein of bacterial Type II CRISPR adaptive immune system (reviewed in <ref name="Prin4">PMID:26432244</ref>). In its native context, Cas9 is an RNA-guided endonuclease that is responsible for targeted degradation of the invading foreign DNA–plasmids and phages. Cas9 is directed to its DNA targets by forming a ribonucleoprotein complex with two small non-coding RNAs: CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA) (Figure 1a). In the less common class 2 CRISPR-Cas systems (types II, V, and VI), which are almost completely restricted to bacteria, the effector complex is represented by a single multidomain protein <ref name="Rev430">doi:10.1038/nrmicro3569</ref>. The best-characterized class 2 effector is Cas9 (type II), the RNA-dependent endonuclease that contains two unrelated nuclease domains, HNH and RuvC, that are responsible for the cleavage of the target and the displaced strand, respectively, in the crRNA–target DNA complex (<scene name='74/746096/Cv3/1'>Domain organization of nuclease lobe of Cas9 from S. pyogenes</scene>, [[4zt0]]). The type II loci also encode a trans-acting CRISPR RNA (tracrRNA) that evolved from the corresponding CRISPR repeat and is essential for pre-crRNA processing and target recognition in type II systems. Cas9 is directed to its DNA targets by forming a ribonucleoprotein complex with these 2 small non-coding RNAs: crRNA and tracrRNA. By elegant engineering, <scene name='74/742625/Cv3/8'>crRNA and tracrRNA can be joined end-to-end and transcribed as a single guide RNA (sgRNA)</scene> ([[4zt9]]<ref name="dCAS9">PMID:26113724</ref>) that too efficiently directs Cas9 protein to DNA targets encoded within the guide sequence of sgRNA <ref name="Jinek">PMID:22745249</ref>:
-
''Examples of 3D structures of CRISPR RNA (crRNA)''
 
-
*<scene name='74/742625/Cv3/1'>CRISPR-Cas Cpf1 endonuclease-crRNA-DNA ternary complex</scene> from ''Acidaminococcus sp. BV3L6'' ([[5kk5]]).
 
-
*<scene name='74/742625/Cv2/10'>Crystal structure of Acidaminococcus sp. Cpf1 in complex with crRNA and target DNA</scene> ([[5b43]]).
 
-
*<scene name='74/742625/Cv2/9'>crRNA-dsDNA hybrid from E. coli</scene> ([[5h9f]]).
 
-
*<scene name='74/742625/Cv2/7'>crRNA-dsDNA hybrid and Cascade proteins from E. coli</scene> ([[4u7u]]).
 
- 
-
Cas9 is directed to its DNA targets by forming a ribonucleoprotein complex with two small non-coding RNAs: CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA) (Figure 2a). By elegant engineering, <scene name='74/742625/Cv3/8'>crRNA and tracrRNA can be joined end-to-end and transcribed as a single guide RNA (sgRNA)</scene> (PDB entry [[4zt9]]<ref name="dCAS9">PMID:26113724</ref>) that too efficiently directs Cas9 protein to DNA targets encoded within the guide sequence of sgRNA <ref name="Jinek">PMID:22745249</ref>:
 
-
 
''Examples of 3D structures of single guide RNA (sgRNA)''
''Examples of 3D structures of single guide RNA (sgRNA)''
*<scene name='74/742625/Cv/42'>Cas9-sgRNA-target DNA complex from Streptococcus pyogenes</scene> ([[5fw2]]).
*<scene name='74/742625/Cv/42'>Cas9-sgRNA-target DNA complex from Streptococcus pyogenes</scene> ([[5fw2]]).
*<scene name='74/742625/Cv2/12'>Cas9-sgRNA-target DNA complex from Streptococcus pyogenes</scene> ([[5b2s]]).
*<scene name='74/742625/Cv2/12'>Cas9-sgRNA-target DNA complex from Streptococcus pyogenes</scene> ([[5b2s]]).
*<scene name='74/742625/Cv2/13'>Cas9-sgRNA-target DNA complex from Francisella tularensis</scene> ([[5b2p]]).
*<scene name='74/742625/Cv2/13'>Cas9-sgRNA-target DNA complex from Francisella tularensis</scene> ([[5b2p]]).
-
*<scene name='74/742625/Cv3/2'>Cas9-sgRNA-target DNA complex from Staphylococcus aureus</scene> ([[4axw]]).
+
*<scene name='74/742625/Cv3/2'>Cas9-sgRNA-target DNA complex from Staphylococcus aureus</scene> ([[4axw]]).
-
 
+
-
The <scene name='74/742625/Cv3/4'>optimal DNA target of the complex is determined by a Watson–Crick base pairing of a short ∼20-nt sequence within sgRNA (within the crRNA in wild-type)</scene>, termed the guide sequence, adjacent to a <scene name='74/742625/Cv3/10'>few nucleotide long conserved motif recognized directly by Cas9 protein (protospacer adjacent motif, PAM)</scene> <ref name="Jinek">PMID:22745249</ref><ref name="Prin6">PMID:22949671</ref>. Despite this, a <scene name='74/742625/Cv/44'>few mismatches between guide sequence and target DNA can be tolerated</scene> <ref name="Jinek">PMID:22745249</ref><ref name="Prin7">PMID:23452860</ref><ref name="Prin8">PMID:23761437</ref><ref name="Prin9">PMID:24837660</ref>, more so within the 5’ proximal position of the guide sequence.
+
-
 
+
-
An interference complex of CRISPR-associated (Cas) proteins uses the mature crRNA as a guide to target and destroy foreign nucleic acids bearing sequence complementarity <ref name="Rev37">doi:10.1038/nature09523</ref><ref name="Rev312">doi:10.1126/science.1159689</ref>. In addition to providing adaptive immunity, the CRISPR pathway can also play a role in endogenous gene regulation. CRISPR loci are flanked by a diverse set of ''cas'' genes that define three major CRISPR types (Types I–III) based on gene conservation and locus organization. The ''cas6'' gene family encodes a set of RNA endonucleases responsible for crRNA processing in Type I and Type III CRISPR systems. Type II systems use a trans-activating RNA (tracrRNA) together with endogenous RNase III for crRNA maturation (Figure 1). Despite minimal sequence homology, Cas6s have several conserved structural features that facilitate binding of both the pre-crRNA and their crRNA product with high affinity. In most CRISPR systems, due to the pseudo-palindromic nature of the repeat sequence,the pre-crRNA adopts a stem loop structure that is bound sequence- and shape-specifically and cleaved at its base.<ref name="Rev3">PMID:25468820</ref> For example, PaeCas6f (Csy4) from ''Pseudomonas aeruginosa'' ([[2xli]]) <scene name='74/742625/Cv4/20'>binds selectively and cleaves pre-crRNAs using phylogenetically conserved serine and histidine residues</scene> in the active site. Some pre-crRNAs are predicted to be unstructured in solution and thus may be bound differently, although base pairing may be stabilized by protein interactions <ref name="Rev310">doi:10.1186/gb-2007-8-4-r61</ref>. In Type I-B, I-C, I-E, and I-F systems, the endoRNase stays bound to the crRNA and assembles into a complex with other Cas proteins for downstream targeting <ref name="Rev312">doi:10.1126/science.1159689</ref>, while in Type I-A and III systems, the crRNA alone is loaded into the targeting complex and Cas6 dissociates <ref name="Rev3">PMID:25468820</ref> (Figure 1). The Type I interference complex is known as '''Cascade''' ('''C'''RISPR-'''as'''sociated '''c'''omplex for '''a'''ntiviral '''de'''fense), the CRISPR subtype from which it derives is denoted with a slash (e.g., the Cascade complex from a Type I-E CRISPR system is known as Cascade/I-E). Type III-A and III-B systems use the Csm and Cmr complex, respectively (Figure 1)<ref name="Rev3">PMID:25468820</ref>.
+
-
 
+
-
=Summary of the most extensively characterized CRISPR endoribonucleases<ref name="Rev3">PMID:25468820</ref><ref name="Rev4">doi:10.1126/science.aad5147</ref>=
+
-
 
+
-
[[Image:CRISPR.jpg|left|450px|thumb|Figure 1. Overview of CRISPR RNA (crRNA) processing and comparison between CRISPR–Cas interference systems. There are three main pathways of CRISPR adaptive immunity (Types I–III) and several subtypes, each typified by a different set of Cas proteins. The first stage of the CRISPR–Cas system is acquisition, in which a foreign DNA sequence is incorporated into the host CRISPR locus. Next, the entire repeat-spacer array is transcribed into a long precursor crRNA (pre-crRNA). A single cleavage within each repeat sequence generates shorter, mature crRNAs. Some crRNAs undergo an additional trimming step. The enzymes responsible for catalysis and exact mode of crRNA processing differ in each system. The crRNA is loaded into an interference complex where it serves as a guide for targeting invasive DNA, or in Type III-B systems, RNA. N- and C-terminal RRM folds are colored teal and gray, respectively. Abbreviations: CRISPR, clustered regularly interspaced short palindromic repeat; Cas, CRISPR-associated; R, repeat; S, spacer; RRM, RNA recognition motif. From <ref name="Rev3">PMID:25468820</ref>]]
+
-
{{Clear}}
+
-
[[Image:F2r.jpg|left|450px|thumb|Figure. 2. CRISPR diversity and evolution. (A) Modular organization of the CRISPR-Cas systems. LS, large subunit; SS, small subunit. A putative small subunit that might be fused to the large subunit in several type I subtypes is indicated by an asterisk. Cas3 is shown as fusion of two distinct genes encoding the helicase Cas3′ and the nuclease HD Cas3′′; in some type I systems, these domains are encoded by separate genes. Functionally dispensable components are indicated by dashed outlines. Cas6 is shown with a thin solid outline for type I because it is dispensable in some systems, and by a dashed line for type III because most systems lack this gene and use the Cas6 provided in trans by other CRISPR-Cas loci. The two colors for Cas4 and C2c2 and three colors for Cas9 and Cpf1 reflect the contributions of these proteins to different stages of the CRISPR-Cas response (see text). The question marks indicate currently unknown components. From <ref name="Rev430">doi:10.1038/nrmicro3569</ref><ref name="Rev4">doi:10.1126/science.aad5147</ref> (B) Evolutionary scenario for the CRISPR-Cas systems. TR, terminal repeats; TS, terminal sequences; HD, HD-family endonuclease; HNH, HNH-family endonuclease; RuvC, RuvC-family endonuclease; HEPN, putative endoribonuclease of HEPN superfamily. Genes and portions of genes shown in gray denote sequences that are thought to have been encoded in the respective mobile elements but were eliminated in the course of evolution of CRISPR-Cas systems. From <ref name="Rev431">doi:10.1016/j.molcel.2015.10.008</ref><ref name="Rev4">doi:10.1126/science.aad5147</ref>]]
+
-
{{Clear}}
+
-
==Representatives of class 1 and class 2==
+
-
Class 1 CRISPR-Cas systems are considered to be the evolutionary ancestral systems. The class 2 systems have evolved from class 1 systems via the insertion of transposable elements encoding various nucleases, and are now being used as tools for genome editing.<ref name="Rev4">doi:10.1126/science.aad5147</ref>
+
-
*'''Class 1:'''
+
-
<scene name='74/742625/Cv/5'>Cascade complex (Subtype I-E)</scene> ([[4qyz]]).
+
-
 
+
-
<scene name='74/742625/Cv5/3'>Cmr complex (Subtype III-B)</scene> ([[3x1l]]).
+
-
*'''Class 2:'''
+
-
<scene name='74/742625/Cv5/6'>Cas9 complex (Subtype II)</scene> ([[5f9r]]).
+
-
 
+
-
<scene name='74/742625/Cv5/8'>Cpf1 complex (Subtype V-A)</scene> [[5b43]].
+
-
==Class 1==
+
-
===CRISPR subtype I-A (Cascade)===
+
-
 
+
-
*'''PhoCas6nc (Cas6a)''' from ''Pyrococcus horikoshii'' ([[3qjl]]). <scene name='74/742625/Cv4/16'>Pf7 RNA is able to mediate dimer formation through an exclusive RNA interface</scene>. Other representatives: [[3qjj]], [[3qjp]]. <ref name="PhoCas6nc">PMID:22238224</ref>
+
-
*'''SsoCas6-1A (Sso2004, Cas6-1 family, SsCas6)''' from ''Sulfolobus solfataricus'' ([[4ill]]). <scene name='74/742625/Cv/45'>Dimeric structure of SsCas6 bound with the 24-mer noncleavable RNA</scene>. Other representatives: [[4ilm]], [[4ilr]]. <ref name="SsoCas6">PMID:23454186</ref>
+
-
*'''SsoCas6-1B (Sso1437, Cas6-1 family, SsoCas6)''' from ''Sulfolobus solfataricus'' ([[3zfv]]). <scene name='74/742625/Cv4/17'>Dimeric structure of SsoCas6-1B</scene>. <ref name="SsoCas61B">PMID:23527601</ref>.
+
-
 
+
-
===CRISPR subtype I-B (Cascade)===
+
-
 
+
-
*'''MmaCas6b (Mm Cas6b)''' from ''Methanococcus maripaludis''. <scene name='74/742625/Cv4/18'>Crystal structure of CRISPR RNA processing endoribonuclease Cas6b</scene> ([[4z7k]]).
+
-
 
+
-
===CRISPR subtype I-B?===
+
-
 
+
-
*'''TthCas6B (TTHB231)''' from ''Thermus thermophilus''. <scene name='74/742625/Cv/46'>Cas6B (TTHB231) product complex</scene> ([[4c9d]]). <ref name="Cas6B">PMID:24150936</ref>. Other representative: [[4c98]].
+
-
 
+
-
===CRISPR subtype I-C (Cascade)===
+
-
 
+
-
*'''Cas5c (Cas5d)''': [[4f3m]] (''Bacillus halodurans''), [[3kg4]] (''Mannheimia succiniciproducens''), [[3vzh]] (''Streptococcus pyogenes''), [[3vzi]] (''Xanthomonas oryzae'')<ref name="Rev3">PMID:25468820</ref>.
+
-
 
+
-
===CRISPR subtype I-E (Cascade)===
+
-
 
+
-
*'''TthCas6e (TTHB192, Cse3)''' from ''Thermus thermophilus''. <scene name='74/742625/Cv4/21'>CRISPR endoribonuclease TthCas6e (Cse3) bound to 20 nt RNA</scene> ([[2y8w]]). Other representatives: [[1wj9]], [[2y8y]], [[2y9h]], [[3qrp]], [[3qrq]], [[3qrr]].
+
-
 
+
-
*'''EcoCas6e (CasE)''' from ''Escherichia coli''. [[4dzd]] (monomer).
+
-
 
+
-
* '''Whole Cascade/I-E''' from ''Escherichia coli'': [[4tvx]], [[4u7u]], [[4qyz]], [[5h9f]], [[5h9e]], [[5cd4]]; see below.
+
-
 
+
-
====Crystal structure of a CRISPR RNA-guided surveillance complex, Cascade, bound to a ssDNA target<ref>PMID:25123481</ref>====
+
-
The <scene name='74/742625/Cv/5'>crystal structure of ssDNA-bound Cascade has the seahorse architecture</scene>. The body is formed by a helical filament of six Cas7 subunits (Cas7.1 to 7.6) wrapped around the crRNA guide, with a head-to-tail dimer of Cse2 (Cse2.1 and Cse2.2) at the belly. Cas6e and the 3′ handle of crRNA cap the Cas7 filament at the head while Cas5 and the 5′ handle cap the tail. The N-terminal base of Cse1 is positioned at the tail of the filament; the C-terminal four-helix bundle contacts Cse2.2. The ssDNA target is juxtaposed to the guide region of the crRNA in a groove formed by the Cas7 filament, the four-helix bundle of Cse1, and the Cse2 dimer.
+
-
*<scene name='74/742625/Cv/6'>90° rotation about axis Z</scene>.
+
-
*<scene name='74/742625/Cv/7'>90° rotation about axis Y</scene>.
+
-
 
+
-
The <scene name='74/742625/Cv/10'>two strands of the guide-target hybrid</scene> do not twist around one another in a helix, but instead adopt an underwound ribbon-like structure reminiscent of a ladder. The 5′ and 3′ ends of the curved target strand are ~102Å apart, roughly the length of straight B-form dsDNA with an identical sequence (~107 Å). The crRNA (green) and ssDNA target (orange) are displayed in a spheres representation. Underwinding is facilitated by <scene name='74/742625/Cv/12'>kinks that occur every sixth base pair in the backbone of both strands of the hybrid</scene> (ribbon representation of the crRNA and ssDNA). <scene name='74/742625/Cv/14'>At each kink, complementary nucleotides are rotated ~90°, in opposing directions, from the axis of the duplex</scene>. Disrupted RNA and DNA nucleotides are colored red and blue, respectively.
+
-
 
+
-
=====Structure of the Cas7 subunit.=====
+
-
 
+
-
Within Cascade, the <scene name='74/742625/Cv/25'>six Cas7 subunits form a right-handed filament</scene>, with a pitch of ~135Å, around the guide target hybrid. <scene name='74/742625/Cv/16'>Rocket representation of one Cas7 colored by domain: thumb (green), fingers (blue), and palm (purple).</scene> The filament is arranged such that the <scene name='74/742625/Cv/17'>thumb of one Cas7 subunit, composed of an extended β hairpin, extends toward the fingers of the adjacent subunit</scene>. <scene name='74/742625/Cv/18'>90° rotation about axis Z</scene>.
+
-
 
+
-
=====Stabilization of the guide-target hybrid by Cas7, Cse1, and Cse2.=====
+
-
<scene name='74/742625/Cv/36'>Each 5-bp segment of the hybrid is situated between the palm of one Cas7 subunit (e.g. Cas7.2) and the fingers of the adjacent subunit (e.g. Cas7.3)</scene>. 5-bp segment is colored red. Extensive contacts between the guide region of the crRNA and the Cas7 filament bury a large portion of the crRNA backbone, leaving the bases solvent-exposed. The absence of direct contacts between protein side chains and bases of the crRNA explains the lack of sequence specificity by Cascade for the guide sequence. <scene name='74/742625/Cv/37'>Close-up view of the bound crRNA</scene>. The DNA target has been removed for clarity. Intercalation by Met166 from Cas7 is highlighted. <scene name='74/742625/Cv/38'>Several highly conserved polar and positively charged residues (Arg20, Lys27, Ser40, Gln42, Lys45, and Lys49 - colored in magenta) from the palm of one Cas7 (e.g. Cas7.3) contact the RNA backbone</scene>, while the <scene name='74/742625/Cv/39'>fingers from the adjacent Cas7 (e.g. Cas7.2) subunit (residues 109-111, 163-169, colored in plum) contact both strands of the hybrid across the minor groove</scene>. Of note, the <scene name='74/742625/Cv/40'>Thumb (colored in olive) of one Cas7 subunit (e.g. Cas7.4) pushes through the guide-target hybrid at the 1-bp gaps</scene>. <scene name='74/742625/Cv/32'>Representation of 5 thumbs protruding guide-target hybrid at the 1-bp gaps</scene>. Each displaced RNA nucleotide adopts the syn conformation, is similarly positioned above the backbone of the downstream RNA, and is contacted by <scene name='74/742625/Cv/41'>residues from both the Cas7 palm (e.g. Cas7.3 palm; Ser43 and Arg46) and thumb (e.g. Cas7.4 thumb; Thr201 and Val203)</scene>. Overview of the <scene name='74/742625/Cv1/2'>interactions between the ssDNA target and Cse2.1, Cse2.2, and Cse1</scene>. The proteins are represented as rockets, the DNA as a surface. The positions of the disrupted DNA nucleotides (royal blue) are indicated.
+
-
 
+
-
=====Interactions capping the tail of Cascade=====
+
-
<scene name='74/742625/Cv/34'>Cas5 caps the tail of the Cas7 filament at the 5′ end of the crRNA</scene>. The structure of Cascade reveals that Cas5 is structurally related to Cas7, as it consists of a palm(residues 1 to 78 and 115 to 224) and a thumb (residues 79 to 114) domain, but lacks a fingers domain. <scene name='74/742625/Cv1/3'>Rocket representation of Cas7 and Cas5 colored by domain: thumb (green), fingers (blue), and palm (purple)</scene>. Close-up view of the <scene name='74/742625/Cv/35'>interaction between Cas5, Cas7.6, and the 5′ hook</scene>.
+
-
 
+
-
====Crystal structure of E. coli Cascade bound to a PAM-containing dsDNA target at 2.45 angstrom resolution<ref>PMID:26863189</ref>====
+
-
 
+
-
<scene name='74/742625/Cv2/4'>Crystal structure of E. coli Cascade bound to a PAM-containing dsDNA target</scene>.
+
-
*<scene name='74/742625/Cv2/9'>crRNA-dsDNA hybrid</scene>.
+
-
*<scene name='74/742625/Cv2/7'>crRNA-dsDNA hybrid and Cascade proteins</scene>.
+
-
*<scene name='74/742625/Cv2/8'>Thumbs of Cas7.2-7.6 protrude crRNA-dsDNA hybrid at the 1-bp gaps</scene>.
+
-
 
+
-
===CRISPR subtype I-F (Cascade)===
+
-
 
+
-
*'''PaeCas6f (Csy4)''' from ''Pseudomonas aeruginosa''. <scene name='74/742625/Cv4/23'>Csy4-crRNA complex</scene> ([[2xlj]]). Other representatives: [[2xlk]], [[4al5]], [[4al6]], [[4al7]].
+
-
 
+
-
===CRISPR subtype I-U ===
+
-
 
+
-
===CRISPR subtype III-A (Csm complex)===
+
-
 
+
-
*<scene name='74/742625/Cv5/1'>Csm3-Csm4 subcomplex</scene> in the type III-A CRISPR-Cas interference complex from ''Methanocaldococcus jannaschii''.
+
-
 
+
-
===CRISPR subtype III-B (Cmr complex)===
+
-
 
+
-
*'''PfuCas6-1 (PfCas6)''' from ''Pyrococcus furiosus''. <scene name='74/742625/Cv4/24'>PfuCas6-1 bound to crRNA</scene> ([[3pkm]]). Other representative: [[3i4h]].
+
-
===CRISPR subtype Orphan===
+
The <scene name='74/742625/Cv3/4'>optimal DNA target of the complex is determined by a Watson–Crick base pairing of a short ∼20-nt sequence within sgRNA (within the crRNA in wild-type)</scene>, termed the guide sequence, adjacent to a <scene name='74/742625/Cv3/10'>few nucleotide long conserved motif recognized directly by Cas9 protein (protospacer adjacent motif, PAM)</scene> <ref name="Jinek">PMID:22745249</ref><ref name="Prin6">PMID:22949671</ref>. Despite this, a <scene name='74/742625/Cv/44'>few mismatches between guide sequence and target DNA can be tolerated</scene> <ref name="Jinek">PMID:22745249</ref><ref name="Prin7">PMID:23452860</ref><ref name="Prin8">PMID:23761437</ref><ref name="Prin9">PMID:24837660</ref>, more so within the 5’ proximal position of the guide sequence.
-
 
+
-
*'''TthCas6A (TTHB78)''' from ''T. thermophilus''. <scene name='74/742625/Cv4/25'>TthCas6A bound to crRNA</scene> ([[4c8z]]). Other representatives: [[4c8y]], [[4c97]].
+
-
 
+
-
===CRISPR subtype IV (Csf1)===
+
-
 
+
-
==Class 2==
+
-
 
+
-
===CRISPR subtype II===
+
-
 
+
-
====Transcriptional regulation with CRISPR-Cas9====
+
-
 
+
-
[[Image:1-s2.0-S0958166916301537-gr1.jpg|left|450px|thumb|'''Figure 3.''' Overview of Cas9 nuclease and dCas9-based transcription factors. (a) Wild-type Cas9 endonuclease guided by crRNA:tracrRNA to a specific site in DNA creates a double-stranded DNA break. (b) dCas9, nuclease deactivated mutant of Cas9, is an RNA programmable DNA binding protein. It can act as a steric repressor of transcription in prokaryotes and eukaryotes. sgRNA is an artificial chimeric molecule consisting of crRNA and tracrRNA molecules connected with a short loop. (c) dCas9 fusion with various transcription effectors can be used to repress or activate transcription. (d) Effector domains can be recruited by sgRNA in addition to dCas9 for enhanced activity. (e) sgRNA can be modified with specific protein binding hairpins to concurrently recruit repressor or activator domains in the same cell.<ref name="Did">PMID:27344519</ref>]]
+
-
{{Clear}}
+
-
 
+
-
Cas9 is a key protein of bacterial Type II CRISPR adaptive immune system (reviewed in <ref name="Prin4">PMID:26432244</ref>). <scene name='74/742625/Cv3/9'>Domain organization of the type II-A Cas9 protein from S. pyogenes</scene> (SpyCas9; PDB entry [[4zt0]]<ref name="dCAS9">PMID:26113724</ref>). In its native context, Cas9 is an RNA-guided endonuclease that is responsible for targeted degradation of the invading foreign DNA–plasmids and phages. Cas9 is directed to its DNA targets by forming a ribonucleoprotein complex with two small non-coding RNAs: CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA) (Figure 3a, see also above ''Examples of 3D structures of CRISPR RNA (crRNA)''). By elegant engineering, <scene name='74/742625/Cv3/8'>crRNA and tracrRNA can be joined end-to-end and transcribed as a single guide RNA (sgRNA)</scene> (PDB entry [[4zt9]]<ref name="dCAS9">PMID:26113724</ref>) that too efficiently directs Cas9 protein to DNA targets encoded within the guide sequence of sgRNA <ref name="Jinek">PMID:22745249</ref> (see also above ''Examples of 3D structures of single guide RNA (sgRNA)''). The <scene name='74/742625/Cv3/4'>optimal DNA target of the complex is determined by a Watson–Crick base pairing of a short ∼20-nt sequence within sgRNA (within the crRNA in wild-type)</scene>, termed the guide sequence, adjacent to a <scene name='74/742625/Cv3/10'>few nucleotide long conserved motif recognized directly by Cas9 protein (protospacer adjacent motif, PAM)</scene> <ref name="Jinek">PMID:22745249</ref><ref name="Prin6">PMID:22949671</ref>. Despite this, a <scene name='74/742625/Cv/44'>few mismatches between guide sequence and target DNA can be tolerated</scene> <ref name="Jinek">PMID:22745249</ref><ref name="Prin7">PMID:23452860</ref><ref name="Prin8">PMID:23761437</ref><ref name="Prin9">PMID:24837660</ref>, more so within the 5’ proximal position of the guide sequence.
+
*<scene name='74/742625/Cv4/3'>When Cas9 is in the apo state, its PAM-interacting cleft is largely disordered</scene><ref name="dCAS9">PMID:26113724</ref> ([[4cmp]]<ref name="CAS9">PMID:24505130</ref>).
*<scene name='74/742625/Cv4/3'>When Cas9 is in the apo state, its PAM-interacting cleft is largely disordered</scene><ref name="dCAS9">PMID:26113724</ref> ([[4cmp]]<ref name="CAS9">PMID:24505130</ref>).
*<scene name='74/742625/Cv4/4'>Pre-target state of CAS9 with sgRNA</scene> ([[4zt0]])<ref name="dCAS9">PMID:26113724</ref>.
*<scene name='74/742625/Cv4/4'>Pre-target state of CAS9 with sgRNA</scene> ([[4zt0]])<ref name="dCAS9">PMID:26113724</ref>.
Line 142: Line 41:
*<scene name='74/742625/Cv4/15'>Cas9 interacts with both separated DNA strands</scene> (sgRNA is not shown).
*<scene name='74/742625/Cv4/15'>Cas9 interacts with both separated DNA strands</scene> (sgRNA is not shown).
-
Cas9 nuclease can be converted into <scene name='74/742625/Cv4/8'>deactivated Cas9 (dCas9)</scene> (PDB entry [[4zt9]]), an RNA-programmable DNA-binding protein, by <scene name='74/742625/Cv4/9'>mutating two key residues within its nuclease domains</scene> (Figure 3b) <ref name="dCAS9">PMID:26113724</ref><ref name="Did">PMID:27344519</ref><ref name="Jinek">PMID:22745249</ref><ref name="Prin6">PMID:22949671</ref>.
+
In the type II-A system, the Cas9-tracrRNA complex and Csn2 are involved in spacer acquisition along with the Cas1-Cas2 complex <ref name="Rev453">doi:10.1101/gad.257550.114</ref><ref name="Rev471">doi:10.1038/nature14245</ref>; the involvement of Cas9 in adaptation is likely to be a general feature of type II systems. Although the key residues of Cas9 involved in PAM recognition are dispensable for spacer acquisition, they are essential for the incorporation of new spacers with the correct PAM sequence <ref name="Rev471">doi:10.1038/nature14245</ref>. The involvement of Cas9 in PAM recognition and protospacer selection <ref name="Rev471">doi:10.1038/nature14245</ref> suggests that in type II systems Cas1 may have lost this role.
 +
 
 +
Cas9 nuclease can be converted into <scene name='74/742625/Cv4/8'>deactivated Cas9 (dCas9)</scene> (PDB entry [[4zt9]]), an RNA-programmable DNA-binding protein, by <scene name='74/742625/Cv4/9'>mutating two key residues within its nuclease domains</scene> (Figure 1b) <ref name="dCAS9">PMID:26113724</ref><ref name="Did">PMID:27344519</ref><ref name="Jinek">PMID:22745249</ref><ref name="Prin6">PMID:22949671</ref>.
In the simplest case, dCas9 can repress transcription by sterically interfering with transcription initiation or elongationby being targeted to the gene of interest with a properly chosen sgRNA <ref name="Jinek">PMID:22745249</ref><ref name="Prin6">PMID:22949671</ref><ref name="Prin7">PMID:23452860</ref><ref name="Prin8">PMID:23761437</ref><ref name="Prin10">PMID:25422271</ref><ref name="Prin11">PMID:26390083</ref><ref name="Prin12">PMID:23849981</ref><ref name="Prin13">PMID:23977949</ref><ref name="Prin14">PMID:24797424</ref>. The repression strength is strongly dependent on the position with respect to the target promoter as well as the nature of promoter itself <ref name="Prin7">PMID:23452860</ref><ref name="Prin8">PMID:23761437</ref><ref name="Prin10">PMID:25422271</ref><ref name="Prin11">PMID:26390083</ref>. In prokaryotes, repression of up to 1000-fold was achieved when targeting dCas9 to either DNA strand within a promoter or to the non-template DNA strand downstream. However, in eukaryotic cells such steric repression is weaker: only up to 2-fold and 20-fold repression was observed with natural promoters in mammalian and yeast cells correspondingly<ref name="Prin7">PMID:23452860</ref><ref name="Prin12">PMID:23849981</ref><ref name="Prin13">PMID:23977949</ref>. As a notable exception, synthetic promoters specifically constructed for direct repression by dCas9 can be repressed up to 100-fold in mammalian cells<ref name="Prin14">PMID:24797424</ref>.
In the simplest case, dCas9 can repress transcription by sterically interfering with transcription initiation or elongationby being targeted to the gene of interest with a properly chosen sgRNA <ref name="Jinek">PMID:22745249</ref><ref name="Prin6">PMID:22949671</ref><ref name="Prin7">PMID:23452860</ref><ref name="Prin8">PMID:23761437</ref><ref name="Prin10">PMID:25422271</ref><ref name="Prin11">PMID:26390083</ref><ref name="Prin12">PMID:23849981</ref><ref name="Prin13">PMID:23977949</ref><ref name="Prin14">PMID:24797424</ref>. The repression strength is strongly dependent on the position with respect to the target promoter as well as the nature of promoter itself <ref name="Prin7">PMID:23452860</ref><ref name="Prin8">PMID:23761437</ref><ref name="Prin10">PMID:25422271</ref><ref name="Prin11">PMID:26390083</ref>. In prokaryotes, repression of up to 1000-fold was achieved when targeting dCas9 to either DNA strand within a promoter or to the non-template DNA strand downstream. However, in eukaryotic cells such steric repression is weaker: only up to 2-fold and 20-fold repression was observed with natural promoters in mammalian and yeast cells correspondingly<ref name="Prin7">PMID:23452860</ref><ref name="Prin12">PMID:23849981</ref><ref name="Prin13">PMID:23977949</ref>. As a notable exception, synthetic promoters specifically constructed for direct repression by dCas9 can be repressed up to 100-fold in mammalian cells<ref name="Prin14">PMID:24797424</ref>.
-
===CRISPR subtype V (Cpf1)===
+
'''Cas9-sgRNA-target DNA complexes from Streptococcus pyogenes:'''
 +
*<scene name='74/746096/Cv3/1'>Domain organization of nuclease lobe of Cas9 from S. pyogenes</scene> ([[4zt0]])
 +
*<scene name='74/742625/Cv/42'>Cas9-sgRNA-target DNA complex from Streptococcus pyogenes</scene> ([[5fw2]]).
 +
*<scene name='74/742625/Cv2/12'>Cas9-sgRNA-target DNA complex from Streptococcus pyogenes</scene> ([[5b2s]]).
 +
*<scene name='74/742625/Cv4/5'>CAS9 with sgRNA and tagret DNA</scene> ([[4oo8]]).
 +
*<scene name='74/742625/Cv4/11'>Cas9-sgRNA-dsDNA complex</scene> ([[5f9r]]).
 +
Other representatives: [[5y36]], [[4un3]].
-
===CRISPR subtype VI (C2c2)===
+
'''For continuation please see [[CRISPR-Cas9 Part II]]'''
 +
=See aslo=
 +
*[[Cas9]]
 +
*[[Endonuclease]]
 +
*[[Cas9 (hebrew)]]
</StructureSection>
</StructureSection>
== References ==
== References ==
<references/>
<references/>
 +
[[Category:Topic Page]]
[[Category:Topic Page]]
[[Category:Crispr]]
[[Category:Crispr]]
[[Category: Crispr-associated]]
[[Category: Crispr-associated]]
[[Category: endonuclease]]
[[Category: endonuclease]]
 +
[[Category: Cas9]]

Current revision

Cas9 complex with RNA (PDB code 4zt0)

Drag the structure with the mouse to rotate

References

  1. 1.0 1.1 1.2 1.3 1.4 Didovyk A, Borek B, Tsimring L, Hasty J. Transcriptional regulation with CRISPR-Cas9: principles, advances, and applications. Curr Opin Biotechnol. 2016 Aug;40:177-84. doi: 10.1016/j.copbio.2016.06.003. Epub, 2016 Jun 23. PMID:27344519 doi:http://dx.doi.org/10.1016/j.copbio.2016.06.003
  2. Brophy JA, Voigt CA. Principles of genetic circuit design. Nat Methods. 2014 May;11(5):508-20. doi: 10.1038/nmeth.2926. PMID:24781324 doi:http://dx.doi.org/10.1038/nmeth.2926
  3. Straubeta A, Lahaye T. Zinc fingers, TAL effectors, or Cas9-based DNA binding proteins: what's best for targeting desired genome loci? Mol Plant. 2013 Sep;6(5):1384-7. doi: 10.1093/mp/sst075. Epub 2013 May 29. PMID:23718948 doi:http://dx.doi.org/10.1093/mp/sst075
  4. Sander JD, Joung JK. CRISPR-Cas systems for editing, regulating and targeting genomes. Nat Biotechnol. 2014 Apr;32(4):347-55. doi: 10.1038/nbt.2842. Epub 2014 Mar 2. PMID:24584096 doi:http://dx.doi.org/10.1038/nbt.2842
  5. Marraffini LA. CRISPR-Cas immunity in prokaryotes. Nature. 2015 Oct 1;526(7571):55-61. doi: 10.1038/nature15386. PMID:26432244 doi:http://dx.doi.org/10.1038/nature15386
  6. Makarova KS, Wolf YI, Alkhnbashi OS, Costa F, Shah SA, Saunders SJ, Barrangou R, Brouns SJ, Charpentier E, Haft DH, Horvath P, Moineau S, Mojica FJ, Terns RM, Terns MP, White MF, Yakunin AF, Garrett RA, van der Oost J, Backofen R, Koonin EV. An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol. 2015 Nov;13(11):722-36. doi: 10.1038/nrmicro3569. Epub 2015, Sep 28. PMID:26411297 doi:http://dx.doi.org/10.1038/nrmicro3569
  7. 7.0 7.1 7.2 7.3 Jiang F, Zhou K, Ma L, Gressel S, Doudna JA. STRUCTURAL BIOLOGY. A Cas9-guide RNA complex preorganized for target DNA recognition. Science. 2015 Jun 26;348(6242):1477-81. doi: 10.1126/science.aab1452. PMID:26113724 doi:http://dx.doi.org/10.1126/science.aab1452
  8. 8.0 8.1 8.2 8.3 8.4 Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012 Aug 17;337(6096):816-21. doi: 10.1126/science.1225829. Epub 2012, Jun 28. PMID:22745249 doi:http://dx.doi.org/10.1126/science.1225829
  9. 9.0 9.1 9.2 Gasiunas G, Barrangou R, Horvath P, Siksnys V. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria. Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):E2579-86. Epub 2012 Sep 4. PMID:22949671 doi:http://dx.doi.org/10.1073/pnas.1208507109
  10. 10.0 10.1 10.2 10.3 Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell. 2013 Feb 28;152(5):1173-83. doi: 10.1016/j.cell.2013.02.022. PMID:23452860 doi:http://dx.doi.org/10.1016/j.cell.2013.02.022
  11. 11.0 11.1 11.2 Bikard D, Jiang W, Samai P, Hochschild A, Zhang F, Marraffini LA. Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res. 2013 Aug;41(15):7429-37. doi: 10.1093/nar/gkt520. Epub 2013, Jun 12. PMID:23761437 doi:http://dx.doi.org/10.1093/nar/gkt520
  12. Kuscu C, Arslan S, Singh R, Thorpe J, Adli M. Genome-wide analysis reveals characteristics of off-target sites bound by the Cas9 endonuclease. Nat Biotechnol. 2014 Jul;32(7):677-83. doi: 10.1038/nbt.2916. Epub 2014 May 18. PMID:24837660 doi:http://dx.doi.org/10.1038/nbt.2916
  13. Jinek M, Jiang F, Taylor DW, Sternberg SH, Kaya E, Ma E, Anders C, Hauer M, Zhou K, Lin S, Kaplan M, Iavarone AT, Charpentier E, Nogales E, Doudna JA. Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation. Science. 2014 Feb 6. PMID:24505130 doi:http://dx.doi.org/10.1126/science.1247997
  14. Nishimasu H, Ran FA, Hsu PD, Konermann S, Shehata SI, Dohmae N, Ishitani R, Zhang F, Nureki O. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell. 2014 Feb 27;156(5):935-49. doi: 10.1016/j.cell.2014.02.001. Epub 2014 Feb, 13. PMID:24529477 doi:http://dx.doi.org/10.1016/j.cell.2014.02.001
  15. Jiang F, Taylor DW, Chen JS, Kornfeld JE, Zhou K, Thompson AJ, Nogales E, Doudna JA. Structures of a CRISPR-Cas9 R-loop complex primed for DNA cleavage. Science. 2016 Jan 14. pii: aad8282. PMID:26841432 doi:http://dx.doi.org/10.1126/science.aad8282
  16. Wei Y, Terns RM, Terns MP. Cas9 function and host genome sampling in Type II-A CRISPR-Cas adaptation. Genes Dev. 2015 Feb 15;29(4):356-61. doi: 10.1101/gad.257550.114. PMID:25691466 doi:http://dx.doi.org/10.1101/gad.257550.114
  17. 17.0 17.1 17.2 Heler R, Samai P, Modell JW, Weiner C, Goldberg GW, Bikard D, Marraffini LA. Cas9 specifies functional viral targets during CRISPR-Cas adaptation. Nature. 2015 Mar 12;519(7542):199-202. doi: 10.1038/nature14245. Epub 2015 Feb, 18. PMID:25707807 doi:http://dx.doi.org/10.1038/nature14245
  18. 18.0 18.1 Nielsen AA, Voigt CA. Multi-input CRISPR/Cas genetic circuits that interface host regulatory networks. Mol Syst Biol. 2014 Nov 24;10:763. doi: 10.15252/msb.20145735. PMID:25422271
  19. 19.0 19.1 Didovyk A, Borek B, Hasty J, Tsimring L. Orthogonal Modular Gene Repression in Escherichia coli Using Engineered CRISPR/Cas9. ACS Synth Biol. 2016 Jan 15;5(1):81-8. doi: 10.1021/acssynbio.5b00147. Epub 2015 , Sep 30. PMID:26390083 doi:http://dx.doi.org/10.1021/acssynbio.5b00147
  20. 20.0 20.1 Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, Stern-Ginossar N, Brandman O, Whitehead EH, Doudna JA, Lim WA, Weissman JS, Qi LS. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013 Jul 18;154(2):442-51. doi: 10.1016/j.cell.2013.06.044. Epub 2013 Jul, 11. PMID:23849981 doi:http://dx.doi.org/10.1016/j.cell.2013.06.044
  21. 21.0 21.1 Farzadfard F, Perli SD, Lu TK. Tunable and multifunctional eukaryotic transcription factors based on CRISPR/Cas. ACS Synth Biol. 2013 Oct 18;2(10):604-13. doi: 10.1021/sb400081r. Epub 2013 Sep, 11. PMID:23977949 doi:http://dx.doi.org/10.1021/sb400081r
  22. 22.0 22.1 Kiani S, Beal J, Ebrahimkhani MR, Huh J, Hall RN, Xie Z, Li Y, Weiss R. CRISPR transcriptional repression devices and layered circuits in mammalian cells. Nat Methods. 2014 Jul;11(7):723-6. doi: 10.1038/nmeth.2969. Epub 2014 May 5. PMID:24797424 doi:http://dx.doi.org/10.1038/nmeth.2969

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky, Michal Harel

Personal tools